Cero Therapeutics Holdings, INC DEF 14A proxy statements

CERo Therapeutics Holdings, Inc. filed a supplement to its definitive proxy statement, clarifying the classification of proposals for its 2025 Special Meeting of Stockholders.

CERo Therapeutics Holdings, Inc. calls a special meeting to approve a reverse stock split, preferred stock issuance, and an increase in its equity incentive plan to address Nasdaq listing requirements and fund operations.

CERO Therapeutics is asking stockholders to approve several key proposals at its upcoming annual meeting, including a reverse stock split to maintain Nasdaq listing, approval of past share issuances, and an increase in the company's equity incentive plan.

CERO Therapeutics Holdings, Inc. is facing delisting from the Nasdaq Global Market due to its common stock trading at $0.10 or less for ten consecutive trading days.

CERo Therapeutics Holdings, Inc. has rescheduled its Autumn 2024 Special Meeting of Stockholders to November 11, 2024, to allow more time for stockholders to vote on key proposals including a reverse stock split and an increase to the equity incentive plan.

CERo Therapeutics is asking stockholders to approve a reverse stock split, the issuance of shares related to convertible preferred stock and warrants, and an increase in the company's equity incentive plan.

CERO Therapeutics announces a second postponement of its special stockholder meeting, now scheduled for September 26, 2024.

CERO Therapeutics Holdings, Inc. announced the postponement of its special meeting of stockholders from September 12, 2024, to September 19, 2024.

CERo Therapeutics Holdings is asking stockholders to approve a reverse stock split to increase its stock price and meet Nasdaq's listing requirements.

CERo Therapeutics Holdings is holding a special meeting of stockholders on April 30, 2024, to vote on proposals including ratification of auditor appointment, approval of common stock issuance, amendment to the equity incentive plan, and adjournment if necessary.